Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer (vol 13, 3334, 2023)

被引：0
作者：
Sauriol, Skye Alexandre
Carmona, Euridice
Udaskin, Molly L.
Radulovich, Nikolina
Leclerc-Desaulniers, Kim
Rottapel, Robert
Oza, Amit M.
Lheureux, Stephanie
Provencher, Diane M.
Mes-Masson, Anne-Marie
机构：
[1] Centre de Recherche du Centre hospitalier de l’Université de Montréal,Princess Margaret Cancer Centre
[2] Institut du Cancer de Montréal,Department of Medical Biophysics
[3] University Health Network,Division of Medical Oncology and Hematology
[4] University of Toronto,Division of Gynecologic Oncology
[5] University of Toronto,Department of Medicine
[6] Université de Montréal,undefined
[7] Université de Montréal,undefined
来源：
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41598-024-60769-1
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：1
相关论文
共 23 条
  • [21] Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
    Razan Sheta
    Magdalena Bachvarova
    Marie Plante
    Marie-Claude Renaud
    Alexandra Sebastianelli
    Jean Gregoire
    Jamilet Miranda Navarro
    Ricardo Bringas Perez
    Jean-Yves Masson
    Dimcho Bachvarov
    Journal of Translational Medicine, 18
  • [22] Clinical Activity of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Rucaparib in Patients (pts) With High-Grade Ovarian Carcinoma (HGOC) and a BRCA Mutation (BRCAmut): Analysis of Pooled Data From Study 10 (Parts 1, 2a, and 3) and ARIEL2 (Parts 1 and 2)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 11 - 12
  • [23] Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
    Kristeleit, R. S.
    Shapira-Frommer, R.
    Oaknin, A.
    Balmana, J.
    Ray-Coquard, I. L.
    Domchek, S.
    Tinker, A. V.
    Castro, C. M.
    Welch, S.
    Poveda, A. M.
    Bell-Mcguinn, K.
    Konecny, G.
    Giordano, H.
    Maloney, L.
    Goble, S.
    Rolfe, L.
    Oza, A.
    ANNALS OF ONCOLOGY, 2016, 27
123